We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2755 94 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2755BTW, carnage in sector continue. REGN is/was hit severely. For good or bad reasoMiljenko Zuanic-last Thursday
2754RE:ADVM My exit vas bit premature, but correct, While no rescMiljenko Zuanic-last Thursday
2753I hope they will be able to compete as stand alone, as well in combination. REGNMiljenko Zuanic-last Wednesday
2752Ahh I see, didn't realize they were trying to go into the same indication asFelix B-last Wednesday
2751No, K-629 results will be compared with Cemiplimab, and IF equivalent (or very sMiljenko Zuanic-last Tuesday
2750Are you saying of Keynote 629 is successful than REGN can compete with them thatFelix B-last Tuesday
2749The next real test for REGN and its PD1 drug, cemiplimab, are Pemb data release Miljenko Zuanic-September 6
2748It is not. siRNA still have to prove itself, and *small* data advantage for Abs Miljenko Zuanic-August 28
2747Is PCSK9 over? endpts.comFelix B-August 28
2746Opthea, OPT-302 Primary outcome achieved: OPT-302 + Lucentis (ranibizumab) combMiljenko Zuanic-August 6
27452Q results: US Eylea and cemiplimab come at nice #. SomeMiljenko Zuanic-August 6
2744I should know better, it is in pre-filled syringe... <1. NAME OMiljenko Zuanic-July 30
2743Thanks. I guess so (crossed my mind). Anyway, REGN need fast E-pre-filled syringMiljenko Zuanic-July 30
2742They may be using the average exchange rate during the quarter rather than the rDewDiligence_on_SI-July 30
2741Just to clarify, based on sale in euro, 1Q=583, 2Q=604, which is 3.6% growth. REMiljenko Zuanic-July 30
2740Eylea, 2Q ex-US sale (reported by Bayer) are e604 ($676, currency exchange rate Miljenko Zuanic-July 30
2739IF one translate today SP action (related to Dem-Gov headline news on healthcareMiljenko Zuanic-July 29
2738Lucentis 2Q US sale (Roche) are at $467M, flat over 1Q-19, and 10% growth over 2Miljenko Zuanic-July 25
2737Beats me! Expecting good 2Q!Miljenko Zuanic-July 22
2736How much will the SP drop after earnings?Felix B-July 22
2735Lucentis 2Q ex-US sale (from Novartis) were $536 m, more or less flat relative tMiljenko Zuanic-July 18
2734Does short have a problem with ADVM? No at 13.5!Miljenko Zuanic-July 8
2733Saga over REGN future continue, and Medicare(CMS) part B is major obstacle. ObviMiljenko Zuanic-July 6
2732Due to its dermatology presence, and to *demoralized* Len self-fulfilling prophMiljenko Zuanic-July 2
2731REGN3500 (anti IL-33 Ab) not as robust as Dupi in asthma control, also no robustMiljenko Zuanic-June 21
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):